WORLDCOIN-FOUNDATION
Worldcoin today introduced a protocol update - World ID 2.0, a more powerful, privacy preserving “humanness” digital passport equipped with exciting app integrations* and a suite of new features. Humanness verification services are expanding in Mexico and Singapore, increasing global access to World ID 2.0.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231213314816/en/
The World ID 2.0 Passport. (Photo: Business Wire)
World ID 2.0 makes it easier to distinguish between bots and verified humans online while preserving privacy with popular apps and services with new pre-built integrations. The protocol will be integrated with popular e-commerce, gaming and social media platforms including: Shopify, Mercado Libre, Minecraft, Reddit and Telegram.
Prove personhood, not identity
The rapid global advancement of artificial intelligence has accelerated the need to differentiate between human- and AI-generated content online. As reported by CNBC, retailers are losing an estimated $100 billion per year from return fraud, bots and coupon stacking. Meanwhile, the digital gaming industry struggles to combat bots impacting the real number of humans playing online and have been alleged to fraudulently beat humans in competitive games.
World ID aims to provide a decentralized digital identity layer that enables anonymous actions for the benefit of every unique human online. With the humanness digital passport, individuals can verify to an app or service that they are human without disclosing their identity, and brands can ensure that their offerings and services are being used as intended. World ID 2.0 also offers new verification levels to provide developers choice when implementing humanness verification requirements into their apps or services.
App integrations deliver greater utility
Users and businesses benefit from World ID. New integrations with apps like Shopify, Telegram, Minecraft, Reddit and Mercado Libre, alongside existing integrations with apps including Discord, Talent Protocol and Okta’s Auth0, mean individuals can quickly and easily verify their humanness on the platforms they use every day. And with a new, high-performance developer platform enabling builders to easily integrate “Sign in with World ID” onto their app, new integrations are being added every week, all visible on the new Worldcoin App Store.
New verification levels offer increased access and flexibility
Nearly five million people globally now have a World ID, and more than 2.5 million have verified their humanness at an Orb so they can fully utilize their World ID.
With its new verification levels, World ID 2.0 introduces more ways for people to use their World ID based on the security needs of the application and to ensure individuals are not sharing more information than they need or want for a given application. From device verification for high convenience and accessibility all the way to Orb verification with additional face authentication for high security use cases, there’s now a way for everyone to use their World ID even if they haven’t yet had the opportunity to verify at an Orb.
How to get a World ID
Obtaining a World ID is as simple as downloading a compatible wallet, starting with the World App which is designed to support 94.5% of the iOS and 98.2% of Android smartphones in use today. Initial verification of a World ID offers a baseline level of protection with Device Auth and an Orb-verified World ID provides enhanced utility for applications or services requiring higher security and verification. Visit https://worldcoin.org/find-orb or check the World App to find an Orb verification location near you.
A look at Worldcoin momentum and expansion
Interest in access to Worldcoin and proof of personhood technologies like World ID is continuing to grow globally. In 2023, World ID verifications jumped from under a million in January to more than 2.5 million by the end of November. Additional Orb locations are also opening in both new and existing cities to help make sure everyone who wants to be a part of the Worldcoin community can do so. Mexico and Singapore join the list of locations where individuals can now find Orbs.
About the Worldcoin Foundation
The Worldcoin Foundation, a steward of the Worldcoin protocol until it is self-sufficient, aims to realize more inclusive, fair and just institutions of governance and of the global digital economy.
About the Worldcoin Protocol
The Worldcoin protocol is intended to be the world’s largest, most inclusive identity and financial public utility and to be accessible by everyone. Worldcoin was originally conceived by Sam Altman, Alex Blania and Max Novendstern. The Worldcoin protocol is designed to empower individuals and organizations around the world with the tools they need to participate in the digital economy and advance humanity's progress. Find out more about Worldcoin at www.worldcoin.org, on Twitter/X, Discord, YouTube and Telegram.
*World ID integrations do not imply World ID is an official product, or a partnership, sponsorship, or endorsement, of the companies whose products were integrated, such as Discord, Mercado Libre, Microsoft, Mojang, Reddit, and Shopify.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20231213314816/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Axelspace: Notice of Signing a Service contract for In-Orbit Demonstration with Pale Blue, Inc.22.12.2025 10:00:00 CET | Press release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” has entered into a service agreement with Pale Blue Inc. (“Pale Blue”), a company that develops, manufactures, and sells thrusters (engines) for small satellites, for an in-orbit demonstration, as detailed below. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219321165/en/ Jun Asakawa, Co-founder & CEO of Pale Blue (left in photo) and Yuya Nakamura, President and CEO of Axelspace Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Under this contract, an in-orbit demonstration of a fast-start Hall thruster developed by Pale Blue is scheduled to be conducted in 2027. Nonetheless, conducting in-orbit demonstrations in a short period of time is known to be a significant challenge due to the in
Axelspace Signing Agreement on a Multi-Launch Arrangement and the Launch of New Satellites with Exolaunch22.12.2025 10:00:00 CET | Press release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” is pleased to announce a multi-launch agreement (MLA) with Exolaunch, a global launch integrator and leader in launch mission management, satellite integration and satellite deployment technologies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219038364/en/ The Multi-Launch Agreement will accelerate the growth of Axelspace. In particular, one satellite scheduled for launch under the new Agreement will be used in the AxelLiner business’s in-orbit demonstration service, “AxelLiner Laboratory”. Exolaunch has already secured launches for eight (8) Axelspace’s satellites on the upcoming missions. Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Nonetheless, conducting in-orbit demonstration
Zambon Biotech Announces First Patient Dosed in Phase 3b ADIP Clinical Study of IPX203 in Parkinson’s Disease22.12.2025 10:00:00 CET | Press release
Zambon Biotech, a specialized biotech company part of the Zambon group that aims to build a scientifically robust and commercially viable portfolio of innovative patient-oriented drugs through the scouting, acquisition, licensing and development of new molecules, today announced that the first participant with advanced Parkinson’s disease has been enrolled in the European Phase 3b ADIP (IPX203 in Advanced Parkinson’s disease) study, which is planned to evaluate the efficacy and safety of IPX203 versus immediate-release (IR) levodopa/carbidopa (LD/CD) in a regimen which has not yet been the focus of a Phase 3 trial. IPX203 is a novel, oral modified-release formulation of LD/CD designed for the treatment of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. IPX203 contains immediate-release granules and extended-release beads, providing both a rapid onset of action and a longer duration of benefit, sustaining the levo
Pimicotinib Approved as Systemic Treatment in China for Tenosynovial Giant Cell Tumor22.12.2025 09:00:00 CET | Press release
First regulatory approval in the world for pimicotinib based on positive data from global Phase 3 MANEUVER studyIn MANEUVER, pimicotinib significantly improved objective response rate at week 25 (54% vs. 3.2% for placebo), while providing clinically meaningful and statistically significant improvements across all patient-reported outcomesWith longer-term follow-up, 3 out of 4 patients treated with pimicotinib achieved response per RECIST v1.1, and treatment continued to be well-toleratedApproval strengthens Merck’s leadership in rare tumors, with additional ongoing regulatory filings for pimicotinib underway globally Merck, a leading science and technology company, announced today that following Priority Review, the China National Medical Products Administration (NMPA) has approved pimicotinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause functional limitation or relatively severe morbidity.
Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma22.12.2025 08:44:00 CET | Press release
Incyte Biosciences Japan G.K. today announced approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for Minjuvi® (tafasitamab) in combination with rituximab and lenalidomide for adult patients with relapsed or refractory follicular lymphoma (2L+ FL). “Today's approval of Minjuvi in combination with rituximab and lenalidomide marks a significant milestone as the first dual-targeted CD19 and CD20 immunotherapy combination for relapsed or refractory FL in Japan,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “By improving progression-free survival, Minjuvi offers a chemotherapy-free option for eligible patients with relapsed or refractory disease. This approval underscores our commitment to bridging critical treatment gaps to patients and families affected by this challenging disease in Japan.” The approval is based on the pivotal Phase 3 inMIND trial, which enrolled 654 adult patients, including patients based in Japan. The study demonstrated that Minjuvi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom